AcquisitionOther
Esperion Therapeutics, Inc. (ESPR) acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Esperion Therapeutics, Inc. (ESPR) -> target · $25,000,000
Term loan amendment to finance portion of Corstasis acquisition.
Open source record (SEC) ↗